Andere talen Ascelia Pharma AB

Aandelen

ACE

SE0010573113

Beurs gesloten - Nasdaq Stockholm Andere beurzen 18:00:00 25-06-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
9,34 ^SEK	-1,68%		+6,99%	+177,15%

17/06	Transcript : Ascelia Pharma AB - Special Call
21/05	Transcript : Ascelia Pharma AB, Q1 2024 Earnings Call, May 21, 2024

Andere talen

Krijg toegang tot al het nieuws: wees als eerste op de hoogte en reageer voordat de beurs dat doet!

Gratis inschrijven

Ascelia Pharma - Time for take-off	20/05
Quarterly Report Q1: Primary Endpoint Met with Strong Headline Results in Orviglance Phase 3 Study	16/05
Ascelia Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024	16/05
Welcome to Ascelia Pharma Investor Update: Bringing Orviglance to Patients	07/05
Bulletin from the Annual General Meeting in Ascelia Pharma AB on 6 May 2024	06/05
Ascelia Pharma Successfully Meets Primary Endpoint with Strong Headline Results in Orviglance Phase 3 Study	02/05
Ascelia Pharma AB Successfully Meets Primary Endpoint with Strong Headline Results in Orvigance Phase 3 Study	02/05
Ascelia Pharma Draws Down SEK 15 Million Second Tranche Under Existing Loan Facility	18/04
Ascelia Pharma Reports SPARKLE Image Reading Completion and Expects Headline Results First Half of May 2024	10/04
Ascelia Pharma Reports SPARKLE Image Reading Completion and Expects Headline Results First Half of May 2024	10/04
Annual Report 2023: Solid Progress with Orviglance Phase 3 Patient Recruitment Completed and Headline Results Expected by May 2024	08/04
Notice of Annual General Meeting in Ascelia Pharma AB	27/03
Ascelia Pharma Q4 2023 - On track with easing financial pressure	12/02
Ascelia Pharma AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	09/02
Q4 and Full Year Report 2023: Strengthened Financial Position Ahead of SPARKLE Phase 3 Study Headline Results in May	09/02
Ascelia Pharma Secures Financing of up to SEK 35 Million	04/02
Orviglance Review Article Published in Investigative Radiology	24/01
Nomination Committee Appointed for AGM 2024 in Ascelia Pharma AB	24/01
Ascelia Pharma Announces Start of Image Reading Phase and Re-confirms Phase 3 SPARKLE Results by May 2024	07/12
Ascelia Pharma AB Announces Start of Image Reading Phase and Re- Confirms Phase 3 SPARKLE Results by May 2024	07/12

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Ascelia Pharma AB

Aandelen

ACE

SE0010573113

Andere talen

Filters